Wed, Sep 17, 2014, 6:05 AM EDT - U.S. Markets open in 3 hrs 25 mins

Recent

% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • rosemariecorbin rosemariecorbin Nov 23, 2011 2:30 PM Flag

    Any Investors Here?

    Over reaction? Hardly.
    The company opened up the possibility that they may withdraw from the Arikace pipeline;;;no one knows the extend of the FDA's actions but for the company to suggest this and offer no direction,I doubt any would invest in Insmed.With 85M and the threat of lawsuits dilution and nothing to offer,the stock may crash far more.This FDA is the worst ever.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Market internals weaken(a/d line very poor) and eventually we will make it down much further,although the market is oversold,so trading bounces will be profitable.I am still in the dollar and a couple stocks with good futures.
      Insmed is dependant on the FDA outcome and the decision strategy of management.The 2 markets will exacerbate the move up or down imho.I had hoped for a rally in INSM,but Insmeds EC was a huge negative.
      I've always been a skeptic here because the biotech sector has a high % of losers and every bio is the next AMGN.I doubt I will be in any market investment in the next few months..hmm doesn't sound joyful,but have a Happy Thanksgiving and be grateful for family.

    • If Whitten is so sure of this product why would a dog study keep us from starting the Phase III now concurrently?

    • No new investor would invest in a company that has so many risks.Leaving the Arikace deal and the teens for sure.

 
INSM
13.25-0.12(-0.90%)Sep 16 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.